Twenty-nine countries join forces to prevent healthcare associated infectious diseases

Over sixty universities, research institutes and companies from twenty-nine European countries will jointly study the impact of applying antimicrobial (nano-)coatings on decreasing the spread of infections. The beneficial aspects of these measures will be assessed in the context of potential environmental adverse effects, as well as development of bacterial resistance. It is the first time that this pressing issue is addressed on such a scale.

Welcome at the AMiCI website!

AMiCI is the acronym of AntiMicrobial Coating Innovations. It is a consortium which was initiated by researchers at the Zuyd University of Applied Sciences in the Netherlands in 2012. AMiCI brings together stakeholders from different countries and disciplines, including knowledge institutes, producers and processors of antimicrobial coatings, and organizations involved in the compliance with international standards on hygiene. The central aim is to evaluate the

Research Coordination and Capacity-building Objectives

The main objective of AMiCI action is to develop, structure, coordinate and maintain a long-term, flexible and open European network in the field of AMC in healthcare. The scientific field encompasses R&D of materials and coatings, testing, legal aspects and cleaning methods. Research coordination will not only include knowledge institutes, such as universities and applied science institutes, but will also incorporate producers, distributors, processors, policy

Rising threats from AntiMicriobial Resistance

Many efforts to reduce AMR have been initiated, are ongoing and have been concluded. However many of these have been proven to be only partially sufficient. In order to succeed, a holistic approach is needed (Communication from the Commission to the European Parliament and the Council – Action plan against the rising threats from Antimicrobial Resistance). AMR is a major European and global societal problem,

AMiCI Action in Relation to Existing Efforts at European Level

Coordination of the best European research resources and capabilities will form the necessary critical mass and develop the most advanced scientific approaches to tackle AMR, reversing its increasing trend, and leading to the sustainable use of antibiotics and treatments for infectious diseases. In this context, the networking efforts of AMICI provide an important link to the EC’s Joint Programming Initiative (JPI) on AMR. This connection

The state-of-the-art in AMC

Novel antibiotic drugs are scarce and increasing resistance against antimicrobial drugs is established. Innovations that tackle rising and prominent threats in healthcare are demanded. Preventive innovations are needed to minimize microbial pressure in bacterial “hotspots”, like hospitals, nursing homes or day-care centres. For example, bacteria can persist for many months on inanimate surfaces, forming an ongoing source of transmission. Healthcare workers can transfer these microbes